cyrilzakka/clinical-trials huggingface dataset:
The Effects of Auditory Cueing on Rhythmic Movement and Cortical Excitability in Patients With Parkinson's Disease

Parkinson's disease (PD) is a progressive degenerative disease of central nervous systems deficit. The clinical symptoms of Parkinson's disease include the following motor tasks: difficult in initiating movement, performing rhythmic movement or serial movement, the ability of learning motor movement is also affected. The primary treatment for Parkinson's disease is medical treatment; surgery is used if in need. Rehabilitation such as physical therapy, which aims to improve patient's quality of life and functions, is a non-invasive treatment and value for PD patients. Auditory cue is a technique that widely applied on training patients with Parkinson's disease, and some researches revealed that auditory cueing could improve motor performance. However, the mechanism under this treatment technique is still unknown.

This study is to investigate the effect of auditory cueing on rhythmic finger movement in patients with Parkinson's disease. To investigate the mechanism under auditory cueing, neurophysiological data such as motor cortex excitability and blood flow in cortical cortex will be obtained by using Transcranial magnetic stimulation (TMS) and near infrared spectroscopy (NIRS).


Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of Parkinson disease

Exclusion Criteria:

* Clinical diagnosis of other neurological diseases
* Dementia
* Been diagnosed with any mental illness
* History of seizures
* Brain trauma
* Body with a pacemaker or other electrical stimulator
* Pregnancy
Comparing Cold Biopsy Forceps Versus Cold Snare Biopsy for Colon Polyps

Comparing the efficacy of cold biopsy forceps versus cold snare biopsy for removing colon polyps.

Polyps were randomized to be treated with either CSP or CFP. After the initial polypectomy, additional EMR was performed at the polypectomy site to assess the presence of residual polyp tissue.

Eligibility Criteria:
Inclusion Criteria:

* patients older than 40 years old and
* patients who are receiving colonoscopies and
* patients who have colon polyps

Exclusion Criteria:

* patients who have not agreed to the study
* patients with bleeding tendencies
Accuracy of Pre-existing Risk Scoring Models for Predicting Acute Kidney Injury in Patients Who Underwent Aortic Surgery Using a Gray Zone Approach

Acute kidney injury after cardiac surgery has been reported to increase morbidity and mortality. Several risk scoring models for prediction of aortic kidney injury after cardiac surgery have been developed. However, predictive accuracy of these models is stil unclear. The aim of this study is to evaluate the accuracy of four pre-existing prediction models using a gray zone approach in patients who underwent aortic surgery in our institution.

Acute kidney injury after cardiac surgery has been reported to increase morbidity and mortality. Several risk scoring models for prediction of aortic kidney injury after cardiac surgery have been developed. However, predictive accuracy of these models is stil unclear. The aim of this study is to evaluate the accuracy of four pre-existing prediction models (AKICS, Wijeysundera, Mehta, and Thakar model)using a gray zone approach in patients who underwent aortic surgery in our institution. Based on receiver operating characteristic (ROC) curve analysis, we will construct a gray zone using the cut-off values with a sensitivity of \< 90%, and a specificity of \< 90% (diagnostic tolerance of 10%).

Eligibility Criteria:
Inclusion Criteria:

* Those who underwent elective or emergency aortic surgery in Samsung Medical Center during between 2004 and 2010.

Exclusion Criteria:

* missing laboratory data
* preoperative hemodialysis
* death during or within 48 hours after surgery
13 Valent Pneumococcal Conjugate Vaccine in Chronic Dialysis Patients

To assess the immunogenicity of the PCV13 (13 valent pneumococcal conjugated vaccine) vaccine as compared to the PPV23 (23 valent pneumococcal polysaccharide vaccine) vaccine in patients treated with chronic hemodialysis that are pre-immunized with the PPSV23 vaccine or are PPV23 vaccine naïve by measuring the ELISA and OPA (opsonophagocytic assay) titers after 4 and 52 weeks.

The immunogenicity of the PCV13 (13 valent pneumococcal conjugated vaccine) vaccine as compared to the PPV23 (23 valent pneumococcal polysaccharide vaccine) vaccine in patients treated with chronic hemodialysis that are pre-immunized with the PPV23 vaccine or are PPV23 vaccine naïve will be measured by ELISA and OPA (opsonophagocytic assay) titers after 4 and 52 weeks.

Eligibility Criteria:
Inclusion Criteria:

1. they are under chronic dialysis treatment
2. are 50 years or older and not pregnant
3. have no immediate life threatening conditions
4. are not allergic to one of the compounds of the vaccine
5. have a known pneumococcal vaccination status
6. give their informed consent.

Exclusion Criteria:

Patients not fulfilling the inclusion criteria.
Reversal of Cognitive Decline (ReCODE) Study

Prospective study on patients enrolled in the ReCODE treatment protocol

The objective of the study is to determine if the ReCODE treatment has a measurable impact on the typical progression of neurocognitive decline observed in patients with Alzheimer's Disease (AD) and patients who are exhibiting Mild Cognitive Impairment (MCI). MCI is often a precursor to an AD diagnosis. For this study, there will be no distinction made between participants who have been diagnosed with AD and those who show signs of MCI.

Eligibility Criteria:
Inclusion Criteria:

* 45 to 76 years old
* Adults of any gender, race or ethnicity
* Subjects must have cognitive impairment as demonstrated by a combination of AQ-21 over 5 and either a MOCA 26 or below or a CNS Vitals screening assessment in the MCI in the bottom 70th percentile or 2 of the subtests in the bottom 50th percentile.
* Proficient in spoken and written English for consenting as well as for study participation.
* Must be able to use a computer and web interface. If assistance is needed, it must be readily available to them.
* Regular access to a computer and an internet connection since certain aspects of the program (e.g. cognitive training) are delivered electronically
* Willing and able to follow the protocol if the treating physician determines that is required for appropriate patient care.

Exclusion Criteria:

* Uncontrolled major medical illness, seizures, cardiovascular or cerebrovascular instability.
* A major psychiatric diagnosis that affects activities of daily living (ADL) or functioning.
* Currently taking psychoactive medications known to impact cognition.
* Use of statin therapy, unless eligible to discontinue.
* Use of anticoagulation therapy or history of deep vein thrombosis.
* MRI findings of hydrocephalus, focal stroke, extensive white matter disease or brain tumor.
* Experienced Traumatic Brain Injury (TBI) that is severe enough that it has an ongoing impact on patient function on a regular basis.
* Lack of support (either family member or caregiver) to assist with following the treatment protocol.
* Active cancer, cancer within the past five years or any history of breast cancer.
* Inability to exercise.
* Inability to use a computer, or no computer access.
* Unwillingness or ineligibility to use bioidentical hormone replacement.
* Pregnancy or any chance of becoming pregnant during the course of the study period.
* Presence of an existing diagnosis of a non-AD neurodegenerative disorder (e.g., Lewy Body Disease, Frontotemporal Disease, Chronic Traumatic Encephalopathy, Korsakoff's Syndrome).
* Diagnosis of cerebrovascular disease as the primary cause of cognitive impairment.
* Previous treatment or experience with ReCODE.
Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)

This was a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, including tolerability, of ISIS 678354 and to assess the efficacy of different doses and dosing regimens of ISIS 678354 for reduction of serum triglyceride (TG) levels in participants with hypertriglyceridemia and established CVD or at a high risk for CVD.


Eligibility Criteria:
Key Inclusion Criteria:

* Clinical diagnosis of CVD (defined as documented coronary artery disease, stroke, or peripheral artery disease).
* Fasting serum triglycerides (TG) greater than or equal to (≥) 200 milligrams per deciliter (mg/dL) (≥ 2.3 millimoles per liter (mmol/L)) and less than or equal to (≤) 500 mg/dL (≥ 5.7 mmol/L) at Screening.
* Fasting TG ≥ 200 mg/dL and ≤ 500 mg/dL at Qualification visit.
* Must be on standard-of-care preventative therapy for known CVD risk factors.

Key Exclusion Criteria:

* Within 6 months of Screening: acute coronary syndrome, major cardiac surgery, or stroke/transient ischemic attack (TIA).
* Within 3 months of Screening: coronary, carotid, or peripheral arterial revascularization, major non-cardiac surgery, or lipoprotein apheresis.
* Heart failure New York Heart Association (NYHA) class IV.
* Type 1 diabetes mellitus.
* Type 2 diabetes mellitus with any of the following:

  * Newly diagnosed within 12 weeks of Screening.
  * Glycated hemoglobin (HbA1c) ≥ 9.0% at Screening.
  * Recent change in anti-diabetic pharmacotherapy (change in dosage or addition of new medication within 12 weeks of Screening \[with the exception of ± 10 units of insulin\].
* Body Mass Index (BMI) greater than (\>) 40 kilograms per square meter (kg/m\^2).
Self-Mobilization Versus Kinesio-Taping on the Cervical Region in Electronic Device Users

The purpose of this clinical trial is to compare the effectiveness of kinesio-taping versus self-mobilization applied to the cervical region of long-duration electronic device users.

There is increasing use of electronic devices among individuals due to technological advancement and increasing work demands. The prolong use of these devices may result to discomfort in the neck and impairments in cervical range of motion, proprioceptive sense, muscle activities, and disability among users of electronic devices. Kinesio-taping and self-mobilization in the cervical region may improve function, and reduce disability. Therefore the aim of this study is to compare the effectiveness of kinesio-taping against self-mobilization among long-duration electronic device users.

Participants will be randomized into either a kinesio-taping or self-mobilization group. Treatment will be administered within a four-week period. Participants will be evaluated at baseline, post-intervention and at one-month follow-up.

Eligibility Criteria:
Inclusion Criteria:

* Complain of pain in the neck
* Using electronic devices (including smart phones, desktop computers, laptops, tablets) for at least 4 hours a day,
* Using electronic devices for at least 6 months,
* Volunteering to participate in the study

Exclusion Criteria:

* Having a history of allergic reaction,
* Having previous cervical pathologies such as cervical spondylolisthesis, disc herniation, rheumatoid arthritis, muscle or ligament injury or strain,
* Having had neck or shoulder surgery,
* Having a neurological deficit (eg numbness, muscle weakness and loss of sensation).
Video Laryngeal Mask Versus Endotracheal Tube Undergoing Laparoscopic Cholecystectomy Surgery

The aim of this study is to investigate the effectiveness of using a video laryngeal mask for airway management in patients undergoing laparoscopic cholecystectomy.

The investigators will compare the time required to secure the airway when inserting a video laryngeal mask (LMA) versus performing endotracheal intubation.

Eligibility Criteria:
Inclusion Criteria:

* Patients over 19 years old
* Patients planned for elective laparoscopic cholecystectomy

Exclusion Criteria:

* High risk of aspiration (e.g. gastro-esophageal reflux disease, hiatus hernia, pregnancy, history of gastrectomy)
* Difficult airway (e.g. limitation of mouth opening, limitation of neck extension, oropharyngeal pathology)
* Obesity (BMI \> 30 kg/m2)
* Tooth mobility
Analgesic Effect of Different Combinations of Dexketoprofen Trometamol With Tramadol Hydrochloride in a Model of Moderate to Severe Pain

The purpose of this study is to evaluate the analgesic efficacy of Dexketoprofen Trometamol and Tramadol Hydrochloride given in combinations and the analgesic efficacy of each single component in comparison to placebo on moderate to severe pain following impacted third mandibular molar tooth extraction. Ibuprofen will be used as an active control to validate the pain model.

The aim of this study is to develop a combination of Dexketoprofen Trometamol (DKP.TRIS) and Tramadol Hydrochloride (TRAM.HCl) for the treatment of acute moderate to severe pain, based on the rationale that more than one drug is necessary in most patients suffering of acute and chronic pain, particularly of moderate to severe intensity.

DKP.TRIS and TRAM.HCl have different mechanisms of action, therefore their combination is expect to result in an additive or synergistic analgesia, thus allowing a decrease in the required doses of the individual agents, and consequently a reduced risk of adverse events In this study, patients who present moderate to severe pain after impacted third mandibular molar tooth extraction will be randomised to a total of 10 treatment arms including 4 combinations of DKP.TRIS + TRAM.HCl, the four corresponding single treatments, placebo and ibuprofen. Treatment administration will be followed by a 24-hour pain and analgesic effect assessment.

Eligibility Criteria:
Inclusion Criteria:

Patients meeting ALL the following criteria will be eligible for entry into the study:

* Male or female patients aged 18 to 70 years old. Females participating in the study must be either: of non-childbearing potential, or willing to use a highly effective contraceptive method.
* Scheduled for outpatient surgical extraction -under local anaesthesia- of third mandibular molar teeth, with at least one of which is fully or partially impacted in the mandible requiring bone manipulation.
* Normal physical examination or without clinically relevant abnormalities.

At randomisation (after surgery):

No intake of analgesics (including prescription and over the counter drugs) within 24h prior to the surgery.

* No complication during the surgery, duration of surgery \< 1 hour and not requiring re-anaesthesia.
* Patients experiencing pain of moderate or higher intensity in the first four hours after the end of surgery.

Exclusion Criteria:

* History of allergy or hypersensitivity to NSAIDs, opioids or acetyl salicylic acid.
* History of asthma, bronchospasm, acute rhinitis, nasal polyps, urticaria or angioneurotic oedema.
* History of peptic ulcer, gastrointestinal disorders by NSAIDs, gastrointestinal bleeding or other active bleedings.
FujiLAM Prospective Evaluation Trial

This is a prospective, multicentre cohort study in which the accuracy and the diagnostic yield of the FujiLAM test will be assessed using a microbiological reference standard, an extended microbiological reference standard and a composite reference standard among inpatient and outpatient people living with HIV (PLHIV).


Eligibility Criteria:
Inclusion Criteria:

* Adult PLHIV (≥18 years), irrespective of their CD4 count and antiretroviral therapy (ART) status, at risk of having pulmonary and/or extra-pulmonary TB
* Inpatients: irrespective of TB symptoms
* Outpatients: at least one of the symptoms suggestive of TB (as defined by WHO\*)
* written informed consent
* willingness to have a trial follow-up visit at 2-3 and 6 months after enrolment (e.g. not planning to relocate)

Exclusion Criteria:

* Current anti-TB treatment \*
* Any anti-TB treatment within 60 days prior to enrolment
* Any isoniazid preventive therapy within 6 months prior to enrolment \* Patients starting anti-TB treatment at the time of enrolment will not be excluded from the trial provided that all trial specimens are collected before starting the 3rd dose of treatment.
Real-World Study of Myopia Prevention and Control in Children

This prospective, school-based cohort study aims to enroll approximately 15,000 primary school students from multiple districts in Shanghai, China and to observe the outcomes on myopia prevention and control in children with varying refractive status (including sufficient hyperopia reserve, relative insufficiency in hyperopia reserve, pre-myopia and myopia) who are exposed to a school-based categorized and integrated interventions strategy in real-world settings.

The primary objective of this study is to observe the change in the incidence and prevalence of myopia as well as the the progression of myopia among primary school students population under a school-based interventions, including increasing outdoor activities and wearing special designed optical lenses. The second objective is to identify factors influencing the outcomes and assess the compliance of different intervention methods. Additionally, a cost-effectiveness analysis will be conducted to assess the implementation process, providing technical solutions and operational models for wider application.


Eligibility Criteria:
Inclusion Criteria:

1. All students from the enrolled schools;
2. Participants must be able to cooperate with and complete all required ophthalmic examinations;
3. Written informed consent must be obtained from their parents or legal guardians.

Exclusion Criteria:

1. Ocular abnormalities (e.g., strabismus, amblyopia, or other significant eye diseases);
2. Systemic diseases that may affect ocular health;
3. Current participation in other myopia intervention programs.
Care Management for Patients With Alzheimer Disease and Their Family Caregivers

This is a clinical trial to test the effectiveness of current guideline for the care of older adults with Alzheimer's disease. The study focuses on the primary care setting using a nurse care manager to facilitate guideline-level care. We are hypothesizing that patients who receive guideline-level care will have fewer behavioral problems than those who receive the usual care provided in primary care settings

The specific aim of this proposal is to conduct a four-year randomized controlled clinical trial to test the efficacy of an integrated program of collaborative care as compared to usual care in improving the process and outcomes of care for older adults with dementia in a primary care setting. The program involves three primary components: (1) A comprehensive screening and diagnosis program in which all older adults aged 65 and older from Wishard's Community Health Centers will be screened for dementia. Patients with evidence of dementia will receive further evaluation to determine an explicit diagnosis. Roudebush VA Medical Center patients aged 65 and older with a diagnosis of dementia will receive further evaluation to determine an explicit diagnosis. (2) A multidisciplinary team approach to care for patients with dementia. This care will be coordinated through a geriatric nurse practitioner or a clinical nurse specialist working in the primary care clinic. The team includes primary care and specialist physicians, psychologist, other health care workers, and relevant social service agencies working to adhere to recommended standards of care for primary care patients with dementia. (3) A proactive longitudinal tracking program in which objective measures of process and outcomes of care are fed back to the collaborative care team so that appropriate changes in the course of therapy can be undertaken.

Although authoritative guidelines for the care of patients with Alzheimer Disease and related disorders have been published, there are no clinical trials that test the impact of close adherence to these guidelines on the outcomes of care for a group of vulnerable older adults in an urban primary care setting. We are hypothesizing that patients with dementia and their caregivers who are exposed to this program will: (1) be more likely to receive the emerging standard of care for dementia, including an explicit diagnosis of dementia and an appropriate level of evaluation, education, and management; (2) be less impaired by psychopathology and behavior disturbances; (3) be less functionally impaired at 1-year and 2-year follow-up.

Eligibility Criteria:
Inclusion Criteria:

* Alzheimers Disease

Exclusion Criteria:

* Inability to understand English
* No telephone
Effect of Creatine Monohydrate on Functional Muscle Strength in Children With FSHD

This multi-centre, randomised, double-blind, placebo-controlled crossover trial will compare changes in strength-related motor function following treatment with creatine monohydrate to treatment with placebo, as measured by the Motor Function Measure, from baseline to 12 weeks. Eligible subjects will undergo baseline assessments then will be randomised to either creatine monohydrate therapy or placebo for three months, followed by a six week wash-out period, then crossover to a further three months of therapy with either placebo or creatine. Subjects will undergo clinical assessments and study safety assessments at the beginning and end of each treatment period. The study will begin recruitment in early 2017.


Eligibility Criteria:
Inclusion Criteria:

* Is between the ages of 5 and 18 years inclusive at the time of randomisation;
* Has a confirmed genetic diagnosis of Facioscapulohumeral Muscular Dystrophy (FSHD) types 1 or 2;
* Has a legally acceptable representative capable of understanding the informed consent document and providing consent on the participant's behalf.

Exclusion Criteria:

* Has clinically significant elevation in plasma creatinine level or unexplained hypertension at screening;
* Has a prior diagnosis of chronic renal failure;
* Has a known hypersensitivity to creatine monohydrate of maltodextrin placebo;
* Patients already taking any medications to increase muscle bulk or strength or concomitant use of regular sodium valproate, corticosteroids of alpha agonists such as salbutamol.